Filed under: Analyst upgrades and downgrades , Best Buy (BBY) , Kimberly-Clark (KMB) , Amgen Inc (AMGN) , Analyst initiations Analyst upgrades Rodman & Renshaw upgraded shares of Amgen (NASDAQ: AMGN ) to Outperform from Market Perform following the positive top line results from the FREEDOM study. The firm established an $80 target. Jefferies upgraded shares to Buy from Hold following the positive top-line efficacy and safety results for Denosumab in PMO as they view it as a "big win." The firm raised their target to $71 from $47. Best Buy (NYSE: BBY ) was upgraded to Buy from Neutral at Banc of America. Goldman upgraded Kimberly Clark (NYSE: KMB ) to Neutral from Sell and Dick's Sporting Good (NYSE: DKS ) to Buy from Neutral. Rowan Companies (NYSE: RDC ) was lifted at JP Morgan to Neutral from Underweight. Analyst downgrades: Jesup & Lamont downgraded shares of Moog (NYSE: MOG.A ) to Neutral from Buy on concerns of the company's high rate of R&D and its relative valuation. Keefe Bruyette downgraded shares of Federated Investors to Market Perform from Outperform following the company's lower than expected Q2 results and cut their target to $35. Ryanair (NASDAQ: RYAAY ) was cut to Hold from Buy at Citigroup. Analyst initiations: Morgan Joseph believes Amgen (NASDAQ: AMGN )'s positive FREEDOM trial results will have a profound and lasting impact on the company's growth but also on its scientific credibility. The firm initiated cover ...